SCHEMBL20720128

SCHEMBL20720128

N[C@H]1c2ccccc2C[C@@H]1CO

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.43
HTR2A P28223 4/20 0.41
SIGMAR1 Q99720 2/20 0.40
OPRM1 P35372 1/20 0.37
RET P07949 1/20 0.37
HTR2C P28335 1/20 0.37
HRH1 P35367 1/20 0.37
GRIN2D O15399 1/20 0.36
GRIN3B O60391 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2A Q12879 1/20 0.36
GRIN2B Q13224 1/20 0.36
GRIN2C Q14957 1/20 0.36
GRIN3A Q8TCU5 1/20 0.36
ANPEP P15144 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15036547 1.00 KDM1A (0.43) KDM1AHTR2ASIGMAR1OPRM1RET
SCHEMBL18766100 1.00 KDM1A (0.43) KDM1AHTR2ASIGMAR1OPRM1RET
SCHEMBL15036590 0.85 KDM1A (0.41) KDM1AHTR2ASIGMAR1OPRM1RET
SCHEMBL15018216 0.85 KDM1A (0.41) KDM1AHTR2ASIGMAR1OPRM1RET
SCHEMBL19523456 0.81 KDM1A (0.43) KDM1AHTR2ASIGMAR1OPRM1RET
SCHEMBL3838497 0.81 KDM1A (0.43) KDM1AHTR2ASIGMAR1OPRM1RET
SCHEMBL13924895 0.81 KDM1A (0.43) KDM1AHTR2ASIGMAR1OPRM1RET
SCHEMBL8582012 0.79 SLC6A12 (0.41) KDM1ASIGMAR1
SCHEMBL4666507 0.78 BLM (0.43) KDM1AOPRM1GRIN2DGRIN3BGRIN1
SCHEMBL17539095 0.78 BLM (0.43) KDM1AOPRM1GRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-11-07 US disclosed
EP-3365334-B1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMA CO LTD (JP) 2024-07-17 EP disclosed
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-26 US disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 KDM1A 372/4885HTR2A 3716/4885SIGMAR1 1921/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 KDM1A 372/4885HTR2A 3716/4885SIGMAR1 1921/4885
US-20240368136-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 KDM1A 369/4885HTR2A 3719/4885SIGMAR1 1923/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 KDM1A 372/4885HTR2A 3716/4885SIGMAR1 1921/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 KDM1A 390/4885HTR2A 3808/4885SIGMAR1 1872/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 KDM1A 372/4885HTR2A 3716/4885SIGMAR1 1921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.